查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1673491

全球心源性休克市場：規模、趨勢、COVID-19 影響分析以及按治療類型、最終用戶和地區分類的 2030 年預測

Global Cardiogenic Shock Market: Analysis By Treatment Type (Drugs, Mechanical Circulatory Support Devices and Others), By End User, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030
出版日期: | 出版商: Daedal Research | 英文 147 Pages | 訂單完成後即時交付

價格

心源性休克是一種危及生命的疾病，患者心臟突然無法泵出足夠的血液來滿足身體的需求。它最常見的原因是嚴重心臟病發作（心肌梗塞），但也可能由其他心臟疾病引起，如心臟衰竭、心律不整、心肌炎和瓣膜疾病。預計2024年全球心源性休克市場規模為35.7億美元，到2030年將達52億美元。

由於心血管疾病（CVD）盛行率不斷上升、先進機械循環支援設備的採用不斷增加以及對早期診斷和治療認知的不斷提高，全球心源性休克市場預計將大幅成長。老年人口的快速增加，以及心臟病的揮發性，進一步加速了市場的擴張。經皮輔助人工心臟(pVAD) 和體外膜氧合 (ECMO) 等治療方案的技術進步正在提高患者的生存率並推動需求。此外，醫療成本的上漲、優惠的報銷政策以及新治療方法臨床試驗數量的增加也促進了市場的成長。人工智慧與診斷工具和即時監測系統的整合也正在改善治療效果，進一步推動全球心源性休克市場的發展。金額2025-2030 年預測期內全球心源性休克市場複合年成長率為 6.47%。

本報告對全球心源性休克市場進行了深入分析，並提供了有關市場動態、COVID-19 的影響和競爭格局的資訊。

目錄

第1章執行摘要

第 2 章 簡介

  • 心源性休克：概述
    • 心源性休克簡介
    • 如何降低心源性休克的風險
  • 心源性休克的細分：概述
    • 心源性休克的細分

第3章 全球市場分析

  • 全球心源性休克市場：分析
    • 全球心源性休克市場概覽
    • 全球心源性休克市場規模
    • 全球心源性休克市場（依治療類型）
    • 全球心源性休克市場（依最終用戶分類）
    • 全球心源性休克市場（按區域）
  • 全球心源性休克市場：治療類型分析
    • 全球心源性休克市場概覽（依治療類型）
    • 藥物性心源性休克治療的全球市場規模
    • 使用機械循環支援 (MCS) 設備進行心源性休克治療的全球市場規模
    • 全球其他心源性休克市場規模
  • 全球心源性休克市場：最終用戶分析
    • 全球心源性休克市場：最終用戶概覽
    • 醫院和診所心源性休克的全球市場規模
    • 專門心臟中心心源性休克的全球市場規模
    • 全球門診手術中心心源性休克市場規模
    • 全球其他心源性休克市場規模

第4章 區域市場分析

  • 北美心源性休克市場：分析
    • 北美心源性休克市場概覽
    • 北美心源性休克市場規模
    • 北美心源性休克市場（按地區）
    • 美國心源性休克市場規模
    • 加拿大心源性休克市場規模
    • 墨西哥心源性休克市場規模
  • 歐洲心源性休克市場：分析
    • 歐洲心源性休克市場概況
    • 歐洲心源性休克市場規模
    • 歐洲心源性休克市場（按地區）
    • 德國心源性休克市場規模
    • 英國心源性休克市場規模
    • 法國心源性休克市場規模
    • 義大利心源性休克市場規模
    • 西班牙心源性休克市場規模
    • 其他歐洲心源性休克市場規模
  • 亞太心源性休克市場分析
    • 亞太地區心源性休克市場概覽
    • 亞太心源性休克市場規模
    • 亞太地區心源性休克市場（按區域）
    • 中國心源性休克市場規模
    • 日本心源性休克市場規模
    • 印度心源性休克市場規模
    • 韓國心源性休克市場規模
    • 其他亞太地區心源性休克市場規模
  • 拉丁美洲心源性休克市場：分析
    • 拉丁美洲心源性休克市場概況
    • 拉丁美洲心源性休克市場規模
  • 中東和非洲心源性休克市場分析
    • 中東和非洲心源性休克市場概況
    • 中東和非洲心源性休克市場規模

第5章 新冠肺炎疫情的影響

  • COVID-19 對全球心源性休克市場的影響
  • COVID-19 對全球心源性休克市場的影響

第6章 市場動態

  • 成長動力
    • 世界老齡人口不斷成長
    • 心臟疾病率增加
    • 醫療費用上漲
    • 久坐生活方式盛行
    • 提高認知和早期診斷
  • 任務
    • 先進治療和設備成本高昂
    • 缺乏熟練的醫護人員
  • 市場趨勢
    • 人工智慧的採用率不斷提高
    • 機械循環支援 (MCS) 設備的技術進步
    • 新型藥物療法的開發
    • 增加研發活動
    • 採用微創技術
    • 對照護現場（POC）檢測的需求不斷增加

第7章 競爭格局

  • 全球心源性休克市場公司：最新發展

第8章 公司簡介

  • Abbott
  • Medtronic plc
  • Boston Scientific Corporation
  • AstraZeneca Plc
  • Roche Holdings AG
  • Bayer AG
  • Getinge
  • Johnson & Johnson (Abiomed)
  • Viatris, Inc.
  • Terumo Corporation
  • Endo International plc (Par Pharmaceutical)
  • Windtree Therapeutics, Inc.
  • ZOLL Medical Corporation

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's needs. It is most commonly caused by a severe heart attack (myocardial infarction) but can also result from other heart conditions such as heart failure, arrhythmias, myocarditis, or valve disorders. The global cardiogenic shock market value in 2024 stood at US$3.57 billion, and is projected to reach US$5.20 billion by 2030.

The global cardiogenic shock market is poised for significant growth, driven by the rising prevalence of cardiovascular diseases (CVDs), increasing adoption of advanced mechanical circulatory support devices, and growing awareness regarding early diagnosis and treatment. The surge in aging populations, who are more prone to heart-related conditions, further accelerates market expansion. Technological advancements in treatment options, such as percutaneous ventricular assist devices (pVADs) and extracorporeal membrane oxygenation (ECMO), are improving patient survival rates and driving demand. Additionally, increasing healthcare expenditures, favorable reimbursement policies, and the rising number of clinical trials for novel therapies contribute to market growth. The integration of artificial intelligence (AI) in diagnostic tools and real-time monitoring systems is also enhancing treatment outcomes, further boosting the global cardiogenic shock market. The global cardiogenic shock market value is projected to grow at a CAGR of 6.47%, during the forecast period of 2025-2030.

Market Segmentation Analysis:

By Treatment Type: According to the report, the global cardiogenic shock market is bifurcated into three segments based on the treatment type: drugs, mechanical circulatory support (MCS) devices and others. Drugs segment acquired majority of share in the market in 2024 due to the widespread use of vasopressors, inotropes, and anticoagulants as first-line treatments to stabilize patients and restore hemodynamic function. These medications are readily available, cost-effective, and crucial for immediate management, contributing to their significant market share. However, the mechanical circulatory support (MCS) devices segment is expected to grow the fastest due to the increasing adoption of advanced life-saving technologies such as intra-aortic balloon pumps (IABPs), percutaneous ventricular assist devices (pVADs), and extracorporeal membrane oxygenation (ECMO). These devices offer superior efficacy in maintaining cardiac output and reducing mortality rates in severe cardiogenic shock cases, especially when drug therapy alone is insufficient. Additionally, continuous technological advancements, increasing clinical evidence supporting their benefits, and growing healthcare investments in critical care infrastructure are fueling the rapid expansion of the MCS devices segment.

By End-user: According to the report, the global cardiogenic shock market is bifurcated into four types of end-users: hospitals & clinics, specialty cardiac centers, ambulatory surgical centers and others. Hospitals segment acquired the majority share in the global cardiogenic shock market in 2024 and is also the fastest-growing segment due to the high patient influx, availability of advanced treatment options, and presence of specialized cardiac care units. Hospitals are the primary centers for managing cardiogenic shock, offering 24/7 emergency care, intensive monitoring, and access to life-saving interventions such as mechanical circulatory support (MCS) devices, extracorporeal membrane oxygenation (ECMO), and catheter-based procedures. The increasing number of hospital admissions due to the rising prevalence of cardiovascular diseases (CVDs) and the growing elderly population further drive this segment's growth. Additionally, hospitals benefit from higher healthcare investments, government funding, and favorable reimbursement policies. The expansion of multi-specialty hospitals and the rising focus on improving critical care infrastructure further contribute to the segment's rapid growth in the global cardiogenic shock market.

By Region: The report provides insight into the cardiogenic shock market based on the geographical operations, namely, North America, Europe, Asia Pacific and rest of the world. North America cardiogenic shock market enjoyed the highest market share in 2024 due to its well-established healthcare infrastructure, high prevalence of cardiovascular diseases (CVDs), and widespread adoption of advanced treatment options. The region also benefits from strong government initiatives, favorable reimbursement policies, and extensive research and development activities aimed at improving cardiogenic shock management. However, the Asia Pacific market is expected to grow the fastest during the forecast period due to the rising incidence of cardiovascular diseases, increasing healthcare expenditure, and improving access to advanced medical treatments. Rapid urbanization, a growing aging population, and lifestyle changes leading to higher risk factors such as diabetes and hypertension further contribute to market expansion. Additionally, the region is witnessing significant investments in healthcare infrastructure, an increasing number of specialized cardiac centers, and greater awareness about early diagnosis and treatment of cardiogenic shock, driving its rapid growth.

Global Cardiogenic Shock Market Dynamics:

Growth Drivers: One of the most important factors driving the growth of global cardiogenic shock market is increase in the global geriatric population. The increasing global geriatric population is a key driver of growth in the cardiogenic shock market, as aging is a major risk factor for cardiovascular diseases (CVDs), including heart attacks, heart failure, and cardiogenic shock. Older adults are more likely to develop comorbidities such as hypertension, diabetes, and atherosclerosis, which contribute to cardiac complications and increase the likelihood of cardiogenic shock. With advancements in healthcare extending life expectancy, the number of elderly individuals requiring critical cardiac care is rising, driving demand for both pharmaceutical and mechanical interventions. Other factors driving the growth of global cardiogenic shock market include increasing incidence of heart disease, growing healthcare expenditure, growing prevalence of sedentary lifestyle, rising awareness and early diagnosis etc.

Challenges: One significant challenge faced by the global cardiogenic shock market is high cost of advanced therapies and devices. The high cost of advanced therapies and mechanical circulatory support (MCS) devices poses a significant challenge to the growth of the global cardiogenic shock market. Treatments such as extracorporeal membrane oxygenation (ECMO), percutaneous ventricular assist devices (pVADs), and intra-aortic balloon pumps (IABPs) are highly effective but come with substantial costs, making them less accessible, especially in low- and middle-income countries. The expenses associated with these technologies include not only the initial procurement but also ongoing maintenance, specialized healthcare personnel, and intensive post-procedure care, further increasing the financial burden on healthcare systems and patients. Another challenge might include shortage of skilled staff etc.

Trends: The adoption of minimally invasive techniques is a significant trend in the global cardiogenic shock market due to their ability to improve patient outcomes while reducing recovery time, complications, and hospital stays. Procedures such as percutaneous coronary intervention (PCI), percutaneous ventricular assist devices (pVADs), and catheter-based extracorporeal membrane oxygenation (ECMO) offer effective support for patients in cardiogenic shock with less trauma compared to traditional open-heart surgeries. These techniques allow for quicker stabilization of patients, leading to lower mortality rates and improved long-term prognosis. Additionally, advancements in interventional cardiology, along with the increasing preference for minimally invasive procedures among physicians and patients, are driving their widespread adoption. The growing availability of specialized catheter-based interventions and the expansion of hybrid operating rooms in hospitals further support this trend. The market is also projected to grow at a fast pace during the forecast period, due to various other latest trends such as rise in adoption of artificial intelligence, technological advancements, development of novel pharmacological therapies, rise in research and development activities, rising demand for point-of-care testing etc.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic initially disrupted the global cardiogenic shock market due to delays in non-emergency cardiac procedures, strained healthcare resources, and supply chain challenges. However, post-COVID-19, the market rebounded with increased investments in critical care infrastructure, growing awareness of cardiovascular complications linked to COVID-19, and accelerated adoption of advanced treatment modalities.

Competitive Landscape and Recent Developments:

The global cardiogenic shock market is characterized by a moderately consolidated landscape, with a few dominant players holding significant market shares, while smaller companies also contribute to the market dynamics. Key players of global cardiogenic shock market are:

Abbott

Medtronic plc

Boston Scientific Corporation

AstraZeneca Plc

Roche Holdings AG

Bayer AG

Getinge

Johnson & Johnson (Abiomed)

Viatris Inc.

Terumo Corporation

Endo International plc (Par Pharmaceutical)

Windtree Therapeutics Inc.

ZOLL Medical Corporation

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their products to emerging markets and more, to maintain a competitive edge in this market. For instance, In October 2024, Abbott announced the initiation of the TEAM-HF clinical trial, a groundbreaking study designed to improve outcomes for patients with worsening heart failure and In January 2024, Windtree Therapeutics announced a licensed agreement with Lee's Pharmaceuticals to develop and commercialize a positive inotropic agent called Istraoxime to improve systolic and diastolic cardiac function.

Table of Contents

1. Executive Summary

2. Introduction

  • 2.1 Cardiogenic Shock: An Overview
    • 2.1.1 Introduction to Cardiogenic Shock
    • 2.1.2 Ways to Reduce Cardiogenic Shock Risk
  • 2.2 Cardiogenic Shock Segmentation: An Overview
    • 2.2.1 Cardiogenic Shock Segmentation

3. Global Market Analysis

  • 3.1 Global Cardiogenic Shock Market: An Analysis
    • 3.1.1 Global Cardiogenic Shock Market: An Overview
    • 3.1.2 Global Cardiogenic Shock Market by Value
    • 3.1.3 Global Cardiogenic Shock Market by Treatment Type
    • 3.1.4 Global Cardiogenic Shock Market by End-user
    • 3.1.5 Global Cardiogenic Shock Market by Region
  • 3.2 Global Cardiogenic Shock Market: Treatment Type Analysis
    • 3.2.1 Global Cardiogenic Shock Market by Treatment Type: An Overview
    • 3.2.2 Global Drugs Cardiogenic Shock Market by Value
    • 3.2.3 Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value
    • 3.2.4 Global Other Cardiogenic Shock Market by Value
  • 3.3 Global Cardiogenic Shock Market: End-user Analysis
    • 3.3.1 Global Cardiogenic Shock Market by End-user: An Overview
    • 3.3.2 Global Hospitals & Clinics Cardiogenic Shock Market by Value
    • 3.3.3 Global Specialty Cardiac Centers Cardiogenic Shock Market by Value
    • 3.3.4 Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value
    • 3.3.5 Global Others Cardiogenic Shock Market by Value

4. Regional Market Analysis

  • 4.1 North America Cardiogenic Shock Market: An Analysis
    • 4.1.1 North America Cardiogenic Shock Market: An Overview
    • 4.1.2 North America Cardiogenic Shock Market by Value
    • 4.1.3 North America Cardiogenic Shock Market by Region
    • 4.1.4 The US Cardiogenic Shock Market by Value
    • 4.1.5 Canada Cardiogenic Shock Market by Value
    • 4.1.6 Mexico Cardiogenic Shock Market by Value
  • 4.2 Europe Cardiogenic Shock Market: An Analysis
    • 4.2.1 Europe Cardiogenic Shock Market: An Overview
    • 4.2.2 Europe Cardiogenic Shock Market by Value
    • 4.2.3 Europe Cardiogenic Shock Market by Region
    • 4.2.4 Germany Cardiogenic Shock Market by Value
    • 4.2.5 United Kingdom Cardiogenic Shock Market by Value
    • 4.2.6 France Cardiogenic Shock Market by Value
    • 4.2.7 Italy Cardiogenic Shock Market by Value
    • 4.2.8 Spain Cardiogenic Shock Market by Value
    • 4.2.9 Rest of Europe Cardiogenic Shock Market by Value
  • 4.3 Asia Pacific Cardiogenic Shock Market: An Analysis
    • 4.3.1 Asia Pacific Cardiogenic Shock Market: An Overview
    • 4.3.2 Asia Pacific Cardiogenic Shock Market by Value
    • 4.3.3 Asia Pacific Cardiogenic Shock Market by Region
    • 4.3.4 China Cardiogenic Shock Market by Value
    • 4.3.5 Japan Cardiogenic Shock Market by Value
    • 4.3.6 India Cardiogenic Shock Market by Value
    • 4.3.7 South Korea Cardiogenic Shock Market by Value
    • 4.3.8 Rest of Asia Pacific Cardiogenic Shock Market by Value
  • 4.4 Latin America Cardiogenic Shock Market: An Analysis
    • 4.4.1 Latin America Cardiogenic Shock Market: An Overview
    • 4.4.2 Latin America Cardiogenic Shock Market by Value
  • 4.5 Middle East & Africa Cardiogenic Shock Market: An Analysis
    • 4.5.1 Middle East & Africa Cardiogenic Shock Market: An Overview
    • 4.5.2 Middle East & Africa Cardiogenic Shock Market by Value

5. Impact of COVID-19

  • 5.1 Impact of COVID-19 on Global Cardiogenic Shock Market
  • 5.2 Post COVID-19 Impact on Global Cardiogenic Shock Market

6. Market Dynamics

  • 6.1 Growth Drivers
    • 6.1.1 Increase in the Global Geriatric Population
    • 6.1.2 Increasing Incidence of Heart Disease
    • 6.1.3 Growing Healthcare Expenditure
    • 6.1.4 Growing Prevalence of Sedentary Lifestyle
    • 6.1.5 Rising Awareness and Early Diagnosis
  • 6.2 Challenges
    • 6.2.1 High Cost of Advanced Therapies and Devices
    • 6.2.2 Shortage of Skilled Healthcare Professionals
  • 6.3 Market Trends
    • 6.3.1 Rise in Adoption of Artificial Intelligence
    • 6.3.2 Technological Advancements in Mechanical Circulatory Support (MCS) Devices
    • 6.3.3 Development of Novel Pharmacological Therapies
    • 6.3.4 Rise in Research and Development Activities
    • 6.3.5 Adoption of Minimally Invasive Techniques
    • 6.3.6 Rising Demand for Point-of-Care (POC) Testing

7. Competitive Landscape

  • 7.1 Global Cardiogenic Shock Market Players: Recent Developments

8. Company Profiles

  • 8.1 Abbott
    • 8.1.1 Business Overview
    • 8.1.2 Operating Segments
    • 8.1.3 Business Strategy
  • 8.2 Medtronic plc
    • 8.2.1 Business Overview
    • 8.2.2 Operating Segments
    • 8.2.3 Business Strategy
  • 8.3 Boston Scientific Corporation
    • 8.3.1 Business Overview
    • 8.3.2 Operating Segments
    • 8.3.3 Business Strategy
  • 8.4 AstraZeneca Plc
    • 8.4.1 Business Overview
    • 8.4.2 Business Strategies
  • 8.5 Roche Holdings AG
    • 8.5.1 Business Overview
    • 8.5.2 Operating Segments
    • 8.5.3 Business Strategy
  • 8.6 Bayer AG
    • 8.6.1 Business Overview
    • 8.6.2 Operating Segments
    • 8.6.3 Business Strategy
  • 8.7 Getinge
    • 8.7.1 Business Overview
    • 8.7.2 Operating Segments
    • 8.7.3 Business Strategy
  • 8.8 Johnson & Johnson (Abiomed)
    • 8.8.1 Business Overview
    • 8.8.2 Business Segments
    • 8.8.3 Business Strategy
  • 8.9 Viatris, Inc.
    • 8.9.1 Business Overview
    • 8.9.2 Operating Segments
    • 8.9.3 Business Strategy
  • 8.10 Terumo Corporation
    • 8.10.1 Business Overview
    • 8.10.2 Operating Segments
    • 8.10.3 Business Strategy
  • 8.11 Endo International plc (Par Pharmaceutical)
    • 8.11.1 Business Overview
    • 8.11.2 Operating Segments
    • 8.11.3 Business Strategy
  • 8.12 Windtree Therapeutics, Inc.
    • 8.12.1 Business Overview
    • 8.12.2 Business Strategy
  • 8.13 ZOLL Medical Corporation
    • 8.13.1 Business Overview
    • 8.13.2 Business Strategy

List of Figures

  • Figure 1: Ways to Reduce Cardiogenic Shock Risk
  • Figure 2: Cardiogenic Shock Segmentation
  • Figure 3: Global Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 4: Global Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 5: Global Cardiogenic Shock Market by Treatment Type; 2024 (Percentage, %)
  • Figure 6: Global Cardiogenic Shock Market by End-user; 2024 (Percentage, %)
  • Figure 7: Global Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 8: Global Drugs Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 9: Global Drugs Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 10: Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 11: Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 12: Global Other Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 13: Global Other Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 14: Global Hospitals & Clinics Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 15: Global Hospitals & Clinics Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 16: Global Specialty Cardiac Centers Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 17: Global Specialty Cardiac Centers Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 18: Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 19: Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 20: Global Others Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 21: Global Others Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 22: North America Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 23: North America Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 24: North America Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 25: The US Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 26: The US Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 27: Canada Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 28: Canada Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 29: Mexico Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 30: Mexico Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 31: Europe Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 32: Europe Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 33: Europe Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 34: Germany Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 35: Germany Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 36: United Kingdom Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 37: United Kingdom Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 38: France Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 39: France Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 40: Italy Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 41: Italy Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 42: Spain Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 43: Spain Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 44: Rest of Europe Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 45: Rest of Europe Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 46: Asia Pacific Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 47: Asia Pacific Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 48: Asia Pacific Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 49: China Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 50: China Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 51: Japan Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 52: Japan Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 53: India Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 54: India Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 55: South Korea Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 56: South Korea Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 57: Rest of Asia Pacific Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 58: Rest of Asia Pacific Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 59: Latin America Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 60: Latin America Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 61: Middle East & Africa Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 62: Middle East & Africa Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 63: Global Percentage Of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
  • Figure 64: Global Trends in Number of Deaths Due to Cardiovascular Diseases; 2019 and 2021 (Million)
  • Figure 65: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
  • Figure 66: Global Prevalence of Insufficient Physical Activity Among Adults; 2010, 2022 and 2030 (Percentage, %)
  • Figure 67: Global Artificial Intelligence (AI) in Healthcare Market; 2021-2030 (US$ Billion)
  • Figure 68: Abbott Sales by Segments; 2023 (Percentage, %)
  • Figure 69: Medtronic plc Net Sales by Segment: 2023 (Percentage, %)
  • Figure 70: Boston Scientific Corp. Net Sales by Segment: 2023 (Percentage, %)
  • Figure 71: Roche Holdings AG Sales by Operating Segment; 2024 (Percentage, %)
  • Figure 72: Bayer AG Net Sales by Segment; 2023 (Percentage, %)
  • Figure 73: Getinge Sales by Segment: 2023 (Percentage, %)
  • Figure 74: Johnson & Johnson Sales by Business Segment; 2023 (Percentage, %)
  • Figure 75: Viatris, Inc. Sales by Segment: 2023 (Percentage, %)
  • Figure 76: Terumo Corporation Revenue by Company: 2023 (Percentage, %)
  • Figure 77: Endo International plc Revenue by Company: 2023 (Percentage, %)